Cusabio Technology LLC

( ) transports thyroid hormones (T4/T3) and vitamin A, ensuring proper metabolic regulation, growth, and visual function. When misfolded, TTR forms amyloid aggregates, the main pathological feature of hereditary transthyretin ( ), leading to nerve and organ damage.

provides high-quality, application-validated TTR reagents, supported by expert technical service.

👉 Discover our full TTR reagent portfolio: bit.ly/4ivP0WW

Down Syndrome (DS), or trisomy 21, is a common chromosomal condition linked to developmental delays, intellectual disabilities, and various health challenges. While DS was misunderstood for centuries, modern research has revealed its distinct nature, separate from thyroid dysfunction.
🔬 Explore DS research related advancements: bit.ly/41ypARv

DYRK1A regulates essential processes like the cell cycle, proliferation, differentiation, and apoptosis. By modulating phosphorylation in various signaling pathways, it influences cellular stability and activity. Abnormal expression or mutations of DYRK1A are linked to diseases like Down syndrome, neurodegenerative disorders, and cancer.

CUSABIO offers high-quality DYRK1A reagents validated for multiple applications, supported by strict quality control and expert technical assistance. bit.ly/4kWzXHw

NKG2D is an activated receptor expressed on the surface of NK cells and CD8+ T cells, playing a critical role in innate immunity by recognizing virus-infected and tumor cells. This makes it a valuable target in CAR-T and CAR-NK cell therapies.
In November 2020, Nkarta Therapeutics marked a milestone with the first patient delivery of NKX101, a universal CAR-NK cell therapy targeting NKG2D for the treatment of relapsed/refractory AML and high-risk MDS. This follows earlier advancements in CAR-T NKG2D therapies, like CYAD-01 in 2018, which reached a major milestone in the treatment of metastatic colorectal cancer and achieved complete remission in patients with r/r AML. The success of NKG2D-based therapies highlights its immense potential in revolutionizing cancer treatment. Read more: bit.ly/3FBToW7

Angiotensin-converting enzyme 2 (ACE2), first identified in 2000, plays a pivotal role in regulating blood pressure and fluid balance as part of the RAAS and KKS systems. This metalloproteinase (805 amino acids) has a crucial extracellular catalytic domain, and its gene is located on the X chromosome. At CUSABIO, we provide high-quality ACE2 reagents backed by rigorous quality control, validated for multiple research applications. bit.ly/4kpyIkd